Our recent studies demonstrated that pyrimidine synthesis inhibitors induce differentiation of myeloid leukemia by activating the ataxia telangiectasia and Rad3-related (ATR)/checkpoint kinase 1 (Chk1) DNA damage signaling pathway via pyrimidine depletion. The gene discussed is CHEK1; the disease is myeloid leukemia.